(Reuters) – British drugmaker GSK said on Thursday it would take a stake in Spero Therapeutics as part of a licensing agreement for the U.S.-based drug developer’s experimental antibiotic for complicated urinary tract infections.
GSK will pay Spero $66 million upfront for the antibiotic tebipenem HBr and buy $9 million of Spero shares, the companies said in a joint statement.
(Reporting by Amna Karimi in Bengaluru; Editing by Sriraj Kalluvila)
